Impact of mass drug administration of dihydroartemisinin piperaquine during the Ebola virus disease outbreak on malaria morbidity and mortality in Uganda

Authors: Musa Odongo, Anthony Nuwa, Jane Irene Nabakooza, Flavia Mpanga, Fred Kagwire, Tonny Kyagulanyi, David Salandini Odong, Richard Kajubi, Denis Rubahika, Maureen Nakirunda, Godfrey Magumba, Jimmy Opigo

Mass drug administration successfully contributed to malaria containment in Mubende and Kassanda districts when health services were disrupted during Ebola virus disease outbreaks.

Between September 2022 and January 2023, there were Ebola virus disease (EVD) outbreaks in Uganda with epicentres in Mubende and Kassanda districts. The World Health Organization recommends mass drug administration (MDA) for malaria in EVD outbreak settings in anticipation of disruptions to routine malaria services. In December 2022, one round of MDA using dihydroartemisinin piperaquine (DP) was implemented, targeting people three months and older. Trained village health teams distributed DP through a door-to-door approach.

This poster was presented at the Multilateral Initiative on Malaria (MIM) Society's 8th Pan-African Malaria Conference.